1405 RESEARCH BLVD, SUITE 125, ROCKVILLE, MD
Reports Second Quarter 2026 Financial Results and Operational Updates
Faeth Therapeutics Enters $150 Million Sales Agreement with TD Securities
Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer
Stockholders Approve 2026 Equity Incentive and Employee Stock Purchase Plans
Other Events
UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Q2
Amended Annual Report
Q1
Q3
FY 2024
S-3ASR
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
S-1MEF